The estimated Net Worth of James R. Kasinger is at least $7.05 Milion dollars as of 10 March 2024. Mr. Kasinger owns over 7,750 units of CRISPR Therapeutics AG stock worth over $2,831,821 and over the last 7 years he sold CRSP stock worth over $0. In addition, he makes $4,218,750 as General Counsel i Secretary at CRISPR Therapeutics AG.
James has made over 12 trades of the CRISPR Therapeutics AG stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 7,750 units of CRSP stock worth $352,160 on 10 March 2024.
The largest trade he's ever made was exercising 27,500 units of CRISPR Therapeutics AG stock on 19 January 2021 worth over $1,415,975. On average, James trades about 4,433 units every 46 days since 2017. As of 10 March 2024 he still owns at least 62,320 units of CRISPR Therapeutics AG stock.
You can see the complete history of Mr. Kasinger stock trades at the bottom of the page.
James R. Kasinger J.D. serves as General Counsel, Secretary of the Company. Prior to joining our company, Mr. Kasinger served as the General Counsel and Secretary of Moderna, Inc., a biotechnology company, from April 2014 to May 2017. Prior to these roles, Mr. Kasinger was a partner at Goodwin Procter LLP, where he represented life sciences, technology and other high-growth companies. Mr. Kasinger started his legal career at Testa, Hurwitz & Thibeault. Mr. Kasinger holds a J.D. from Boston College Law School and a B.A. from Wheaton College.
As the General Counsel i Secretary of CRISPR Therapeutics AG, the total compensation of James Kasinger at CRISPR Therapeutics AG is $4,218,750. There are 3 executives at CRISPR Therapeutics AG getting paid more, with Samarth Kulkarni having the highest compensation of $16,265,700.
James Kasinger is 48, he's been the General Counsel i Secretary of CRISPR Therapeutics AG since 2017. There are 9 older and 6 younger executives at CRISPR Therapeutics AG. The oldest executive at CRISPR Therapeutics AG is Katherine High, 68, who is the Independent Director.
James's mailing address filed with the SEC is C/O CRISPR THERAPEUTICS, 105 WEST FIRST STREET, BOSTON, MA, 02127.
Over the last 8 years, insiders at CRISPR Therapeutics AG have traded over $284,003,967 worth of CRISPR Therapeutics AG stock and bought 3,347,446 units worth $53,410,590 . The most active insiders traders include Plc Gsk, Ali Behbahani oraz Corp /De/ Celgene. On average, CRISPR Therapeutics AG executives and independent directors trade stock every 13 days with the average trade being worth of $2,405,548. The most recent stock trade was executed by Julianne Bruno on 20 June 2024, trading 7,000 units of CRSP stock currently worth $318,080.
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
CRISPR Therapeutics AG executives and other stock owners filed with the SEC include: